Vertex PharmaceuticalsVRTXEarnings & Financial Report
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Revenue
$2.8B
Gross Profit
$2.4B
Operating Profit
$1.1B
Net Profit
$1.0B
Gross Margin
85.8%
Operating Margin
40.3%
Net Margin
37.7%
YoY Growth
11.6%
EPS
$4.01
Vertex Pharmaceuticals Q3 FY2024 Financial Summary
Vertex Pharmaceuticals reported revenue of $2.8B (up 11.6% YoY) for Q3 FY2024, with a net profit of $1.0B (up 1.0% YoY) (37.7% margin). Cost of goods sold was $392.6M, operating expenses totaled $1.3B.
Key Financial Metrics
| Total Revenue | $2.8B |
|---|---|
| Net Profit | $1.0B |
| Gross Margin | 85.8% |
| Operating Margin | 40.3% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Vertex Pharmaceuticals Q3 FY2024 revenue of $2.8B breaks down across 3 segments, led by TRIKAFTAKAFTRIO at $2.6B (93.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| TRIKAFTAKAFTRIO | $2.6B | 93.3% |
| Manufactured Product Other | $186.9M | 6.7% |
| CASGEVY | $2.0M | 0.1% |
Vertex Pharmaceuticals Revenue by Segment — Quarterly Trend
Vertex Pharmaceuticals revenue by segment across the last 4 reported quarters, showing how each business line (such as TRIKAFTAKAFTRIO and Manufactured Product Other) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| TRIKAFTAKAFTRIO | — | $2.6B | $2.7B | $2.6B |
| Manufactured Product Other | — | $237.4M | $175.8M | $236.1M |
| CASGEVY | $42.9M | — | $16.9M | $30.4M |
Vertex Pharmaceuticals Annual Revenue by Year
Vertex Pharmaceuticals annual revenue history includes year-by-year totals (for example, 2025 revenue was $12.0B).
| Year | Annual Revenue |
|---|---|
| 2025 | $12.0B |
| 2024 | $11.0B |
| 2023 | $9.9B |
| 2022 | $8.9B |
Vertex Pharmaceuticals Quarterly Revenue & Net Profit History
Vertex Pharmaceuticals results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $3.0B | +7.8% | $1.0B | 34.5% |
| Q4 FY2025 | $3.2B | +9.5% | $1.2B | 37.3% |
| Q3 FY2025 | $3.1B | +11.0% | $1.1B | 35.2% |
| Q2 FY2025 | $3.0B | +12.1% | $1.0B | 34.8% |
| Q1 FY2025 | $2.8B | +3.0% | $646.3M | 23.3% |
| Q4 FY2024 | $2.9B | +15.7% | $913.0M | 31.4% |
| Q3 FY2024 | $2.8B | +11.6% | $1.0B | 37.7% |
| Q2 FY2024 | $2.6B | +6.1% | $-3.6B | -135.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.65B | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
| YoY Growth | 6.1% | 11.6% | 15.7% | 3.0% | 12.1% | 11.0% | 9.5% | 7.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $20.13B | $22.24B | $22.53B | $22.88B | $24.04B | $24.86B | $25.64B | $26.48B |
| Liabilities | $5.36B | $6.61B | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B | $7.12B |
| Equity | $14.77B | $15.63B | $16.41B | $16.50B | $17.18B | $17.32B | $18.67B | $19.36B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-3.75B | $1.37B | $584.6M | $818.9M | $1.07B | $1.24B | $498.0M |